Improving the Pipeline for Developing and Testing Pharmacological Treatments in Pregnancy

English version České info

In a Perspective, Lucy Chappell and Anna David discuss ways to develop and test pharmacological treatments in pregnancy.

Vyšlo v časopise: Improving the Pipeline for Developing and Testing Pharmacological Treatments in Pregnancy. PLoS Med 13(11): e32767. doi:10.1371/journal.pmed.1002161
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002161

Souhrn

In a Perspective, Lucy Chappell and Anna David discuss ways to develop and test pharmacological treatments in pregnancy.

Zdroje

1. Ito S, Pariente G, Leibson T, Carls A, Adams-Webber T, Koren G. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med. 2016.

2. Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proceedings of the National Academy of Sciences of the United States of America. 2009 May 26;106(21):8573–8. 19433787. Pubmed Central PMCID: 2688998. doi: 10.1073/pnas.0901505106

3. Goodman A, Schorge J, Greene MF. The long-term effects of in utero exposures—the DES story. The New England journal of medicine. 2011 Jun 2;364(22):2083–4. 21506735. doi: 10.1056/NEJMp1104409

4. Fisk NM, Atun R. Market failure and the poverty of new drugs in maternal health. PLoS Med. 2008 Jan 22;5(1):e22. 18215109. Pubmed Central PMCID: 2211556. doi: 10.1371/journal.pmed.0050022

5. Glover DD, Amonkar M, Rybeck BF, Tracy TS. Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. American journal of obstetrics and gynecology. 2003 Apr;188(4):1039–45. doi: 10.1067/mob.2003.223 12712107.

6. Herring C, McManus A, Weeks A. Off-label prescribing during pregnancy in the UK: an analysis of 18,000 prescriptions in Liverpool Women's Hospital. The International journal of pharmacy practice. 2010 Aug;18(4):226–9. 20636674. doi: 10.1211/ijpp.18.04.0007

7. van Vliet EO, Boormans EM, de Lange TS, Mol BW, Oudijk MA. Preterm labor: current pharmacotherapy options for tocolysis. Expert opinion on pharmacotherapy. 2014 Apr;15(6):787–97. 24533566. doi: 10.1517/14656566.2014.889684

8. UK Teratology Information Service. http://www.uktis.org/ (accessed 8 September 2016)

9. Chambers C. The role of teratology information services in screening for teratogenic exposures: challenges and opportunities. American journal of medical genetics Part C, Seminars in medical genetics. 2011 Aug 15;157C(3):195–200. 21748849. doi: 10.1002/ajmg.c.30303

10. Godfrey KM, Barker DJ. Fetal programming and adult health. Public health nutrition. 2001 Apr;4(2B):611–24. doi: 10.1079/PHN2001145 11683554.

11. Van Riet-Nales DA, Kozarewicz P, Aylward B, de Vries R, Egberts TC, Rademaker CM, et al. Paediatric Drug Development and Formulation Design-a European Perspective. AAPS PharmSciTech. 2016 Jun 7. E-pub ahead of print. 27270905. doi: 10.1208/s12249-016-0558-3 27270905

12. Food U.S. and Drug Administration. Pregnancy and Lactation Labeling (Drugs) Final Rule. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm (accessed 8 September 2016)

13. David AL, Thornton S, Sutcliffe A, Williams P. Developing New Pharmaceutical Treatments for Obstetric Conditions: Scientific Impact Paper No. 50. Royal College of Obstetricians and Gynaecologists, 2015. https://www.rcog.org.uk/globalassets/documents/guidelines/scientific-impact-papers/sip-50.pdf